inclusion criteria: 1. patients with covid-19 who need supplemental oxygen 2. women must not be pregnant or breastfeeding, and must be surgically sterile or in the postmenopausal stage (without risk of becoming pregnant). 3. men must be surgically sterile or abstinent or, if they are having sex with risk of pregnancy, the subject must use an effective method of contraception from the moment they sign the informed consent form until at least 24 weeks after the dose of the study drug (isis 721744 or placebo).

inclusion criteria: 1. patients with covid-19 who need supplemental oxygen 2. women must not be pregnant or breastfeeding, and must be surgically sterile or in the postmenopausal stage (without risk of becoming pregnant). 3. men must be surgically sterile or abstinent or, if they are having sex with risk of pregnancy, the subject must use an effective method of contraception from the moment they sign the informed consent form until at least 24 weeks after the dose of the study drug (isis 721744 or placebo).

inclusion criteria: patients with covid-19 who need supplemental oxygen women must not be pregnant or breastfeeding, and must be surgically sterile or in the postmenopausal stage (without risk of becoming pregnant). men must be surgically sterile or abstinent or, if they are having sex with risk of pregnancy, the subject must use an effective method of contraception from the moment they sign the informed consent form until at least 24 weeks after the dose of the study drug (isis 721744 or placebo).

inclusion criteria: patients with covid-19 who need supplemental oxygen women must not be pregnant or breastfeeding, and must be surgically sterile or in the postmenopausal stage (without risk of becoming pregnant). men must be surgically sterile or abstinent or, if they are having sex with risk of pregnancy, the subject must use an effective method of contraception from the moment they sign the informed consent form until at least 24 weeks after the dose of the study drug (isis 721744 or placebo).

inclusion criteria: 1. patients with covid-19 who need supplemental oxygen 2. women must not be pregnant or breastfeeding, and must be surgically sterile or in the postmenopausal stage (without risk of becoming pregnant). 3. men must be surgically sterile or abstinent or, if they are having sex with risk of pregnancy, the subject must use an effective method of contraception from the moment they sign the informed consent form until at least 24 weeks after the dose of the study drug (isis 721744 or placebo).

inclusion criteria: 1. patients with covid-19 who need supplemental oxygen 2. women must not be pregnant or breastfeeding, and must be surgically sterile or in the postmenopausal stage (without risk of becoming pregnant). 3. men must be surgically sterile or abstinent or, if they are having sex with risk of pregnancy, the subject must use an effective method of contraception from the moment they sign the informed consent form until at least 24 weeks after the dose of the study drug (isis 721744 or placebo).

inclusion criteria: 1. patients with covid-19 who need supplemental 2. women must not be pregnant or breastfeeding, and must be surgically sterile or in the postmenopausal stage (without risk of becoming pregnant). 3. men must be surgically sterile or abstinent or, if they are having sex with risk of pregnancy, the subject must use an effective method of contraception from the moment they sign the informed consent form until at least 24 weeks after the dose of the study drug (isis 721744 or placebo).

inclusion criteria: 1. patients with covid-19 who need supplemental 2. women must not be pregnant or breastfeeding, and must be surgically sterile or in the postmenopausal stage (without risk of becoming pregnant). 3. men must be surgically sterile or abstinent or, if they are having sex with risk of pregnancy, the subject must use an effective method of contraception from the moment they sign the informed consent form until at least 24 weeks after the dose of the study drug (isis 721744 or placebo).

inclusion criteria: 1. patients with covid-19 who need supplemental oxygen of at least 2l/min (≥ 2l/min) through a nasal catheter (or equivalent) to obtain a peripheral oxygen saturation ≥ 95% 2. women must not be pregnant or breastfeeding, and must be surgically sterile or in the postmenopausal stage (without risk of becoming pregnant). 3. men must be surgically sterile or abstinent or, if they are having sex with risk of pregnancy, the subject must use an effective method of contraception from the moment they sign the informed consent form until at least 24 weeks after the dose of the study drug (isis 721744 or placebo).

inclusion criteria: 1. patients with covid-19 who need supplemental oxygen of at least 2l/min (≥ 2l/min) through a nasal catheter (or equivalent) to obtain a peripheral oxygen saturation ≥ 95% 2. women must not be pregnant or breastfeeding, and must be surgically sterile or in the postmenopausal stage (without risk of becoming pregnant). 3. men must be surgically sterile or abstinent or, if they are having sex with risk of pregnancy, the subject must use an effective method of contraception from the moment they sign the informed consent form until at least 24 weeks after the dose of the study drug (isis 721744 or placebo).